Hemagen Diagnostics, Inc. (HMGN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hemagen Diagnostics, Inc. (HMGN) trades at $0.0002 with AI Score 39/100 (Grade D). Hemagen Diagnostics, Inc. develops and markets clinical diagnostic solutions for human and veterinary applications. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HMGN: HMGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HMGN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HMGN: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Hemagen Diagnostics, Inc. (HMGN) Healthcare & Pipeline Overview
Hemagen Diagnostics, Inc. is a biotechnology company specializing in human and veterinary clinical diagnostic solutions, primarily immunoassays for autoimmune and infectious diseases. With a focus on direct and distributor sales, Hemagen serves laboratories, hospitals, and blood banks globally, operating in the competitive diagnostic market.
What Is the Investment Thesis for HMGN?
Hemagen Diagnostics, Inc. presents a focused investment opportunity within the biotechnology sector, specifically in the clinical diagnostics market. The company's specialization in immunoassays for autoimmune and infectious diseases provides a degree of market niche. A key value driver is the potential for increased adoption of its VIRGO line and specialty assays. However, potential investors may want to evaluate the company's negative profit margin of -22.4% and the competitive landscape. Growth catalysts include expanding distribution networks and developing new diagnostic assays. The company's beta of 0.36 suggests lower volatility compared to the broader market. The absence of a dividend may deter some investors seeking income.
Based on FMP financials and quantitative analysis
HMGN Key Highlights
Hemagen Diagnostics, Inc. operates with a relatively small team of 15 employees, indicating a lean operational structure.
- The company's gross margin stands at 39.9%, reflecting its ability to manage production costs effectively.
- Hemagen Diagnostics, Inc. has a beta of 0.36, suggesting lower volatility compared to the overall market.
- The company's profit margin is -22.4%, indicating current challenges in achieving profitability.
- Hemagen Diagnostics does not currently offer a dividend, which may influence investor interest.
Who Are HMGN's Competitors?
HMGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HMGN's Key Strengths?
Specialized expertise in immunoassays.
- Established VIRGO product line.
- Direct sales and distribution network.
- Proprietary assays and technologies.
What Are HMGN's Weaknesses?
Negative profit margin.
- Limited scale compared to larger competitors.
- Dependence on a relatively small number of products.
- OTC market listing may limit investor access.
What Could Drive HMGN Stock Higher?
Expansion of distribution networks in emerging markets to increase market reach.
- Development and launch of new specialty assays for niche applications within the next 2-3 years.
- Strategic partnerships and acquisitions to expand product portfolio and access new technologies.
What Are the Key Risks for HMGN?
Financial-distress signal — its Altman Z-Score of -14.16 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from larger diagnostic companies with greater resources.
- Regulatory changes affecting diagnostic testing and approval processes.
- Patent expirations on key products, leading to generic competition.
- Negative profit margin indicating financial challenges.
What Are the Growth Opportunities for HMGN?
- Expanding the VIRGO product line: Hemagen has the opportunity to expand its VIRGO line of immunoassays to cover a broader range of autoimmune and infectious diseases. The global immunoassay market is projected to reach $34.1 billion by 2027, growing at a CAGR of 6.8%. By investing in research and development to introduce new assays, Hemagen can capture a larger share of this growing market. Timeline: 2-3 years for new product development and regulatory approvals.
- Strengthening distribution networks: Hemagen can increase its market reach by expanding its distribution networks, particularly in emerging markets. The global diagnostics market is experiencing rapid growth in regions like Asia-Pacific and Latin America. By partnering with local distributors, Hemagen can access these markets and increase its sales volume. Timeline: 1-2 years for establishing new distribution partnerships.
- Developing specialty assays: Hemagen can capitalize on the growing demand for specialty assays by developing new diagnostic tests for niche applications. This includes assays for rare diseases, personalized medicine, and companion diagnostics. The market for specialty assays is characterized by higher margins and less competition. Timeline: 2-3 years for research, development, and regulatory approvals.
- Enhancing veterinary diagnostic offerings: Hemagen can leverage its existing expertise in veterinary diagnostics to develop new and innovative products. The global veterinary diagnostics market is projected to reach $6.2 billion by 2028, growing at a CAGR of 9.2%. By expanding its product portfolio and targeting specific animal health needs, Hemagen can strengthen its position in this market. Timeline: 1-2 years for new product development and market launch.
- Strategic partnerships and acquisitions: Hemagen can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. This includes partnering with other diagnostic companies, research institutions, or technology providers. Strategic acquisitions can provide Hemagen with access to complementary products, technologies, or distribution networks. Timeline: Ongoing, with potential deals occurring within the next 1-3 years.
What Are HMGN's Competitive Advantages?
- Specialized expertise in immunoassays for autoimmune and infectious diseases.
- Established VIRGO product line with a recognized brand in the diagnostics market.
- Direct sales and distribution network providing access to key customer segments.
- Proprietary assays and technologies offering differentiation from competitors.
What Does HMGN Do?
Founded in 1985 and based in Columbia, Maryland, Hemagen Diagnostics, Inc. is a biotechnology company providing clinical diagnostic solutions for human and veterinary applications. The company's core business revolves around the development, manufacture, and marketing of diagnostic products, with a primary focus on immunoassays. Its VIRGO line of immunoassays is used for the diagnosis of autoimmune and infectious diseases, as well as acute phase proteins. Hemagen's human diagnostics product line includes Universal IFA components, supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialty assays for conditions like Chagas disease, acute phase proteins, and cytokines. In addition to its human diagnostics offerings, Hemagen provides a range of veterinary diagnostic products. These include equipment, reagents, supplies, accessories, and electrodes used in chemistry, hematology, and electrolyte analysis. The company distributes its products through a combination of direct sales and a network of distributors, serving a diverse customer base that includes laboratories, hospitals, and blood banks worldwide. Hemagen's market position is characterized by its specialized focus on niche diagnostic areas and its established presence in both the human and veterinary clinical diagnostics markets.
What Products and Services Does HMGN Offer?
- Develops and manufactures human clinical diagnostic products.
- Offers immunoassays for diagnosing autoimmune and infectious diseases.
- Provides veterinary diagnostic products for animal health.
- Markets the VIRGO line of immunoassays.
- Sells products directly to laboratories, hospitals, and blood banks.
- Distributes products through a network of distributors worldwide.
- Offers specialty assays for conditions like Chagas disease.
How Does HMGN Make Money?
- Develops and manufactures diagnostic assays and related products.
- Sells diagnostic products directly to end-users, such as laboratories and hospitals.
- Distributes products through a network of distributors to expand market reach.
- Generates revenue from the sale of reagents, equipment, and accessories.
What Industry Does HMGN Operate In?
Hemagen Diagnostics, Inc. operates within the biotechnology industry, specifically in the clinical diagnostics segment. This segment is characterized by continuous innovation, driven by the need for more accurate and efficient diagnostic tools. The market is competitive, with established players and emerging companies vying for market share. Key trends include the increasing adoption of immunoassay-based diagnostics and the growing demand for veterinary diagnostic solutions. Hemagen's focus on specialized assays positions it within a niche market, but it faces competition from larger diagnostic companies like BSYI, DRWN, EMDF, FFNTF, and GSAC.
Who Are HMGN's Key Customers?
- Clinical laboratories
- Hospitals
- Blood banks
- Veterinary clinics and hospitals
Company Profile
Hemagen Diagnostics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Columbia, US. The company is led by CEO William Hales. HMGN has traded publicly since 1993.
Hemagen Diagnostics, Inc. (HMGN) Valuation Context
Relative to its peer group, HMGN's quantitative score of 39/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Hemagen Diagnostics, Inc. stands at 29.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.1%, showing how much profit it generates from its asset base. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Hemagen Diagnostics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.16 places it in the distress zone, a signal of elevated financial risk.
HMGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized expertise in immunoassays.
- Established VIRGO product line.
- Direct sales and distribution network.
- Proprietary assays and technologies.
Bear Case
- Negative profit margin.
- Limited scale compared to larger competitors.
- Dependence on a relatively small number of products.
- OTC market listing may limit investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
HMGN Latest News
No recent news available for HMGN.
HMGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HMGN.
Price Targets
Wall Street price target analysis for HMGN.
HMGN MoonshotScore
What does this score mean?
The MoonshotScore rates HMGN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: William Hales
CEO
William Hales serves as the CEO of Hemagen Diagnostics, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing its operations in the biotechnology and clinical diagnostics sectors. With a focus on innovation and market expansion, Hales is responsible for driving the development and commercialization of Hemagen's diagnostic solutions.
Track Record: As CEO, William Hales manages a team of 15 employees and is responsible for the overall performance of Hemagen Diagnostics, Inc. Key achievements under his leadership include maintaining the company's position in the diagnostics market and overseeing the development of new assays. His strategic decisions focus on expanding the company's product portfolio and distribution network.
HMGN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hemagen Diagnostics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies are subject to stricter listing standards and regulations.
- OTC Tier: OTC Other
- Limited financial disclosure increases investment risk.
- Lower trading volume and liquidity can lead to price volatility.
- OTC listing indicates potential financial or operational challenges.
- Regulatory oversight is less stringent compared to major exchanges.
- Potential for fraud or manipulation is higher on the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's capital structure and debt levels.
- Check for any pending lawsuits or investigations.
- Consult with a qualified financial advisor.
- Company has been in business since 1985.
- Focus on specialized diagnostic solutions.
- Direct sales and distribution network.
- Established VIRGO product line.
HMGN Healthcare Stock FAQ
What does the AI Score mean for HMGN?
HMGN holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Hemagen Diagnostics, Inc. develops and markets clinical diagnostic solutions for human and veterinary applications. The company focuses on immunoassays for autoimmune and infectious diseases …
What does Hemagen Diagnostics, Inc. do?
Hemagen Diagnostics, Inc. is a biotechnology company that develops, manufactures, and markets clinical diagnostic solutions for both human and veterinary applications. Their primary focus is on immunoassays, which are used to diagnose autoimmune and infectious diseases. The company's VIRGO line of immunoassays is a key product, and they also offer specialty assays for conditions like Chagas disease.
What do analysts say about HMGN stock?
As of March 17, 2026, there is no readily available analyst coverage for Hemagen Diagnostics, Inc. (HMGN) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for HMGN?
The main risks for Hemagen Diagnostics, Inc. include competition from larger diagnostic companies, regulatory changes affecting diagnostic testing, and patent expirations on key products. The company's negative profit margin indicates financial challenges, and its OTC listing increases investment risk due to limited financial disclosure and lower liquidity. Investors should also be aware of the potential for economic downturns impacting healthcare spending and the company's ability to maintain its market position.
How does Hemagen Diagnostics, Inc. navigate regulatory approval processes?
As a biotechnology company providing clinical diagnostic solutions, Hemagen Diagnostics, Inc. must adhere to stringent regulatory approval processes, primarily from the FDA in the United States and similar bodies in other regions where it sells its products.
How does Hemagen Diagnostics, Inc. manage patent expiration risks?
Hemagen Diagnostics, Inc., like other biotechnology companies, faces the risk of patent expirations on its key diagnostic assays and technologies. To mitigate this risk, Hemagen must continuously invest in research and development to develop new and innovative products that are protected by patents. Additionally, the company may pursue strategies such as extending patent protection through modifications or improvements to existing products, or licensing technologies from other companies.
What are the key factors to evaluate for HMGN?
Hemagen Diagnostics, Inc. (HMGN) holds an AI score of 39/100 (low). presents a focused investment opportunity within the biotechnology sector, specifically in the clinical diagnostics market. Not financial advice.
How frequently does HMGN data refresh on this page?
HMGN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HMGN's recent stock price performance?
Hemagen Diagnostics, Inc. (HMGN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in immunoassays. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Financial data is limited.